Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/76433
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia |
Author: | Yin, O. Giles, F. Baccarani, M. le Coutre, P. Chiparus, O. Gallagher, N. Saglio, G. Hughes, T. Hochhaus, A. Kantarjian, H. Larson, R. |
Citation: | Cancer Chemotherapy and Pharmacology, 2012; 70(2):345-350 |
Publisher: | Springer |
Issue Date: | 2012 |
ISSN: | 0344-5704 1432-0843 |
Statement of Responsibility: | Ophelia Q. P. Yin, Frank J. Giles, Michele Baccarani, Philipp le Coutre, Ovidiu Chiparus, Neil Gallagher, Giuseppe Saglio, Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Richard A. Larson |
Abstract: | <h4>Purpose</h4>The impact of proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2 blockers) on the efficacy of nilotinib was evaluated.<h4>Methods</h4>Retrospective analyses were performed in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP; N = 492) and in patients with imatinib-resistant or imatinib-intolerant Ph+ CML-CP (N = 256) treated with nilotinib.<h4>Results</h4>In the newly diagnosed population, 87 (17.7 %) and 49 (10.0 %) patients received PPIs and H2 blockers, respectively. Major molecular response at 12 months was achieved by 59 (49.6 %) patients who received at least one PPI or H2 blocker (n = 119) and 153 (41.0 %) patients who did not receive any comedication (n = 373; P = 0.13). PPIs and H2 blockers were used by 77 (30.1 %) and 17 (6.6 %) patients with imatinib-resistant or imatinib-intolerant CML-CP, respectively. Major cytogenetic response by 12 months was achieved by 55 (64.0 %) patients who received at least one PPI or H2 blocker (n = 86) versus 98 (57.6 %) patients who did not receive any comedication (n = 170; P = 0.40); 39 (45.3 %) versus 65 (38.2 %), respectively, achieved complete cytogenetic response by 12 months (P = 0.34). Similar findings were observed in patients who received comedication for >50 % of the time on nilotinib therapy. Nilotinib steady-state trough concentration was not affected by the presence of PPIs or H2 blockers.<h4>Conclusions</h4>Concurrent use of PPIs or H2 blockers did not affect the pharmacokinetics and efficacy of nilotinib in patients with Ph+ CML-CP. |
Keywords: | Nilotinib Drug–drug interactions Proton pump inhibitors H2 blockers Chronic myeloid leukemia |
Rights: | © Springer-Verlag 2012 |
DOI: | 10.1007/s00280-012-1881-3 |
Published version: | http://dx.doi.org/10.1007/s00280-012-1881-3 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.